Page 1 Page 2>

Pfenex Statement on Announcement by CMS to Establish Separate J-Codes for Biosimilars

Pfenex’s New CEO Sizes Up Biosimilar Industry’s Future

Sandoz Inc. v. Amgen Inc. at the Supreme Court: Expediting Access to Affordable Biosimilars

Moving the Needle on REMS Legislation – An op-ed from Pfenex CEO Patrick Lucy

Bringing Biosimilars to Market

BsUFA Delays Biosimilar Guides, But FDA Says Interchangeability On Track

Breaking Down Barriers to Patient Access

FDA says trust and education critical for biosimilars

Bio-synonyms: describing biosimilars without saying ‘copycats’ or ‘knock-offs’

Pfenex Inc. Announces Formation of Scientific Advisory Board